Akebia Ther
Price & Volume
Stats
See more52W Range | $1.49-$4.07 |
Market Cap | $419.2M |
Shares Short | 35M |
Financials
See moreRevenue (12 Mos) | $225M |
Revenue Growth (YoY) | 57% |
Gross Profit (12 Mos) | $187.5M |
Diluted EPS | -$0.08 |
News
See moreYahoo Finance • 20 days ago
Akebia signals 7x increase in patient access for Vafseo entering 2026 amid operational focus
Yahoo Finance • 24 days ago
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs
Yahoo Finance • last month
Biggest stock movers Wednesday: JOBY, ENPH, and more
Yahoo Finance • last month
Akebia plummets as it abandons Vafseo for non-dialysis patients
About
CEO | Mr. John P. Butler MBA |
CFO | Mr. Erik John Ostrowski M.B.A. |
Address | 245 First Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 181 |
